Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-55f67697df-px5tt Total loading time: 0 Render date: 2025-05-10T02:00:46.997Z Has data issue: false hasContentIssue false

Chapter 10 - Clozapine

from Part 2 - Psychopharmacology of the Main Psychotropic Drug Groups

Published online by Cambridge University Press:  29 May 2020

By
Richard Drake
Edited by
Peter M. Haddad  and
David J. Nutt
Peter M. Haddad
Affiliation:
Hamad Medical Corporation, Qatar
David J. Nutt
Affiliation:
Centre for Neuropsychopharmacology, Division of Psychiatry, Department of Brain Sciences, Imperial College London
Get access

Summary

Clozapine is a dopamine receptor antagonist that blocks a range of other monoamine receptors and may have some effects on the glutamatergic system. There is evidence that it has better efficacy and effectiveness than other dopamine antagonists in treating schizophrenia that has failed to respond to other dopamine receptor antagonists. It appears to reduce impulsive behaviours such as violence (Frogley et al., 2011), self-harm (Meltzer et al., 2003) and substance misuse (Lalanne et al., 2016) and to have mood-stabilizing properties (Chang et al., 2006). In the UK it is licensed for three indications: (i) treatment-resistant schizophrenia, (ii) for treating schizophrenia when other antipsychotics have led to severe neurological adverse reactions and (iii) treating psychosis associated with Parkinson’s disease where standard treatment has failed (electronic Medicines Compendium, 2019).

Type
Chapter
Information
Seminars in Clinical Psychopharmacology , pp. 326 - 349
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Agid, O, Arenovich, T, Sajeev, G, et al. (2011). An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry, 72, 1439–1444.Google Scholar
Bagnall, AM, Jones, L, Ginnelly, L, et al. (2003). A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess, 7(13), 1–193.Google Scholar
Barber, S, Olotu, U, Corsi, M, Cipriani, A (2017). Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev, (3), CD006324.Google Scholar
Barnes, TR; Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011). Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 25, 567–620.CrossRefGoogle ScholarPubMed
Barnes, TRE, Drake, RJ, Dunn, G, et al. (2013). The effect of prior treatment with long-acting injectable antipsychotic drugs on randomised, clinical trial treatment outcomes. Br J Psychiatry, 203(3), 215–220.Google Scholar
Barnes, TRE, Dye, S, Ferrier, N, et al. (2014). Consensus Statement on High-Dose Antipsychotic Medication. College Report CR190. London: Royal College of Psychiatrists.Google Scholar
Beri, A, Boydell, J (2014). Clozapine in borderline personality disorder: a review of the evidence. Ann Clin Psychiatry, 26(2), 139–144.Google Scholar
Bowskill, S, Couchman, L, MacCabe, JH, Flanagan, RJ (2012). Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65 years and over: data from a therapeutic drug monitoring service, 1996–2010. Hum Psychopharmacol, 27(3), 277–283.Google Scholar
Brosda, J, Jantschak, F, Pertz, HH (2014). Alpha2-adrenoceptors are targets for antipsychotic drugs. Psychopharmacology, 231(5), 801–812.CrossRefGoogle ScholarPubMed
Chang, A, Fox, SH (2016). Psychosis in Parkinson’s disease: epidemiology, pathophysiology, and management. Drugs, 76(11), 1093–1118.CrossRefGoogle ScholarPubMed
Chang, JS, Ha, KS, Young Lee, K, Sik Kim, Y, Min Ahn, Y (2006). The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry, 67(3), 461–467.Google Scholar
Cohen, D (2017). Clozapine and gastrointestinal hypomotility. CNS Drugs, 31(12), 1083–1091.Google Scholar
Cohen, D, Bogers, JP, van Dijk, D, Bakker, B, Schulte, PF (2012). Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry, 73(10), 1307–1312.CrossRefGoogle ScholarPubMed
Correll, CU, Rubio, JM, Inczedy-Farkas, G, et al. (2017). Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry, 74, 675–684.Google Scholar
Couchman, L, Morgan, EL, Spencer, EP, Flanagan, RJ (2010). Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993–2007. Ther Drug Monit, 32, 438–447.Google Scholar
Crilly, J (2007). The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry, 18(1), 39–60.Google Scholar
Davies, LM, Lewis, S, Jones, PB, et al.; CUtLASS team (2007). Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry, 191, 14–22.CrossRefGoogle Scholar
Davis, JM, Chen, N, Glick, ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry, 60(6), 553–564.CrossRefGoogle ScholarPubMed
Demjaha, A, Egerton, A, Murray, RM, et al. (2014). Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry, 75(5), e11–e13.Google Scholar
Dzahini, O, Singh, N, Taylor, D, Haddad, PM (2018). Antipsychotic drug use and pneumonia: systematic review and meta-analysis. J Psychopharmacol, 32(11), 1167–1181.Google Scholar
electronic Medicines Compendium (2019). Summary of Product Characteristics: Clorazil. Mylan. Last updated 6 June 2019. Available at: www.medicines.org.uk/emc/product/10290/smpc (last accessed 4.10.19).Google Scholar
Fabrazzo, M, La Pia, S, Monteleone, P, et al. (2002). Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology, 27(6), 1050–1055.CrossRefGoogle Scholar
Foley, DL, Mackinnon, A, Morgan, VA, et al. (2015). Effect of age, family history of diabetes, and antipsychotic drug treatment on risk of diabetes in people with psychosis: a population-based cross-sectional study. Lancet Psychiatry, 2(12), 1092–1098.Google Scholar
Frogley, C, Taylor, D, Dickens, G, Picchioni, M (2011). A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol, 15(9), 1351–1371.CrossRefGoogle Scholar
Galling, B, Roldán, A, Hagi, K, et al. (2017). Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.World Psychiatry, 16(1), 77–89.CrossRefGoogle ScholarPubMed
Goldstein, ME, Anderson, VM, Pillai, A, Kydd, RR, Russell, BR (2015). Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. Int J Neuropsychopharmacol, 18(6), 117.Google ScholarPubMed
Gross, G, Wicke, K, Drescher, KU (2013). Dopamine D3 receptor antagonism – still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol, 386(2), 155–166.Google Scholar
Haddad, PM, Correll, CU (2018). The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol, 8(11), 303–318.CrossRefGoogle ScholarPubMed
Haddad, PM, Wieck, A (2004). Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs, 64, 2291–2314.CrossRefGoogle ScholarPubMed
Hampson, M, Killaspy, H, Mynors-Wallis, L, Meier, R (2011). Outcome measures recommended for use in adult psychiatry. Occasional Paper OP78. London: Royal College of Psychiatrists. Available at: www.rcpsych.ac.uk/files/pdfversion/OP78x.pdf (last accessed 11.8.17).Google Scholar
Healy, D (1997). The Psychopharmcologists: Interviews by David Healy. New York: Chapman and Hall.Google Scholar
Holt, RIG, Peveler, RC (2009). Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metabol, 11, 665–679.Google Scholar
Howes, OD, Vergunst, F, Gee, S, et al. (2012). Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry, 201, 481–485.Google Scholar
Howes, OD, McCutcheon, R, Agid, O, et al. (2017). Treatment resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry, 174(3), 216–229.Google Scholar
Huang, KL, Fang, CJ, Hsu, CC, et al. (2017). Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies. J Psychopharmacol, 31(12), 1544–1555. doi:10.1177/0269881117714047.Google Scholar
Hung, GC, Liu, HC, Yang, SY, et al. (2016). Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control study. J Clin Psychiatry, 77, 60–66.CrossRefGoogle ScholarPubMed
Hynes, C, Keating, D, McWilliams, S, et al. (2015). Glasgow Antipsychotic Side-effects Scale for Clozapine – development and validation of a clozapine-specific side-effects scale. Schizophr Res, 168(1–2), 505–513.Google Scholar
Ifteni, P, Nielsen, J, Burtea, V, et al. (2014). Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatr Scand, 130, 25–29.Google Scholar
Ismail, Z, Wessels, AM, Uchida, H, et al. (2012). Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry, 20(1), 53–60.Google Scholar
Kane, JM, Honigfield, G, Singer, J, Meltzer, HY (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 45, 789–796.Google Scholar
Kluge, M, Schuld, A, Schacht, A, et al. (2009). Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology, 34(1), 118–128.Google Scholar
Koponen, HJ, Hakko, HH, Saari, KM, et al. (2010). The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study. World J Biol Psychiatry, 11(2 Pt 2), 262–267.Google Scholar
Krawiecka, M, Goldberg, D, Vaughan, M. (1977). A standardised psychiatric assessment scale for rating chronic psychiatric patients. Acta Psychiatr Scand, 55, 299–308.CrossRefGoogle Scholar
Kuo, CJ, Yang, SY, Liao, YT, et al. (2013). Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull, 39, 648–657.Google Scholar
Lahti, RA, Evans, DL, Stratman, NC, Figur, LM (1993). Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol, 236(3), 483–486.Google Scholar
Lalanne, L, Lutz, PE, Trojak, B, et al. (2016). Medications between psychiatric and addictive disorders. Prog Neuropsychopharmacol Biol Psychiatry, 65, 215–223.Google Scholar
Lally, J, Tully, J, Robertson, D, et al. (2016). Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res, 171(1–3), 215–224.Google Scholar
Lambert, M, Haro, JM, Novick, D, et al. (2005). Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand, 111(3), 232–243.Google Scholar
Lambiase, PD, de Bono, JP, Schilling, RJ, et al. (2019). British Heart Rhythm Society clinical practice guidelines on the management of patients developing QT prolongation on antipsychotic medication. Arrhythm Electrophysiol Rev, 8(3), 161–165.Google Scholar
Laroche, DG, Gaillard, A (2016). Induced obsessive compulsive symptoms (OCS) in schizophrenia patients under atypical 2 antipsychotics (AAPs): review and hypotheses. Psychiatry Res, 246, 119–128.Google Scholar
Leucht, S, Cipriani, A, Spijeli, L, et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 382, 951–962.Google Scholar
Lewis, SW, Barnes, TR, Davies, L, et al. (2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull, 32(4), 715–723.Google Scholar
Li, XB, Tang, YL, Wang, CY, et al. (2015). Clozapine for treatment-resistant bipolar disorder: a systematic review. Bipolar Disord, 17, 235–247.Google Scholar
Lieberman, JA, Phillips, M, Gu, H, et al. (2003). Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology, 28(5), 995–1003.Google Scholar
Lobos, CA, Komossa, K, Rummel-Kluge, C, et al. (2010). Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, (11), CD006633.Google Scholar
Manu, P, Sarpal, D, Muir, O, Kane, JM, Correll, CU (2012). When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res, 134(2–3), 180–186.Google Scholar
Manu, P, Lapitskaya, Y, Shaikh, A, Nielsen, J (2018). Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases. Am J Ther, 25(2), e218–e223.CrossRefGoogle ScholarPubMed
Mauri, MC, Volonteri, LS, Colasanti, A, et al. (2007). Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet, 46(5), 359–388.Google Scholar
McEvoy, JP, Lieberman, JA, Stroup, TS, et al.; CATIE Investigators (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry, 163(4), 600–610.Google Scholar
Melkersson, K, Lewitt, M, Hall, K (2015). Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. Neuro Endocrinol Lett, 36(5), 465–480.Google Scholar
Meltzer, HY (2013). Update on typical and atypical antipsychotic drugs. Annu Rev Med, 64, 393–406.Google Scholar
Meltzer, HY, Alphs, L, Green, AI, et al.; International Suicide Prevention Trial Study Group (2003). Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry, 60, 82–91.Google Scholar
Mendoza, MC, Lindenmayer, JP (2009). N-desmethylclozapine: is there evidence for its antipsychotic potential? Clin Neuropharmacol, 32(3), 154–157.CrossRefGoogle ScholarPubMed
Meyer, N, Gee, S, Whiskey, E, et al. (2015). Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. J Clin Psychiatry, 76(11), e1410–e1416.CrossRefGoogle ScholarPubMed
Miyamoto, S, Miyake, N, Jarskog, LF, Fleischhacker, WW, Lieberman, JA (2012). Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry, 17(12), 1206–1227.Google Scholar
Morrison, AP, Pyle, M, Gumley, A, et al. (2019). Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT. Health Technol Assess, 23(7), 1–144.Google Scholar
Mouchlianitis, E, Bloomfield, MA, Law, V, et al. (2016). Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull, 42(3), 744–752.Google Scholar
National Institute for Health and Care Excellence (NICE) (2014). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]. London: National Institute for Health and Care Excellence. Available at: www.nice.org.uk/guidance/cg178 (last accessed 4.10.19).Google Scholar
Nielsen, J, Meyer, JM (2012). Risk factors for ileus in patients with schizophrenia. Schizophr Bull, 38(3), 592–598.CrossRefGoogle ScholarPubMed
Nielsen, J, Correll, CU, Manu, P, Kane, JM (2013). Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry, 74(6), 603–613.CrossRefGoogle ScholarPubMed
Norman, SM, Sullivan, KM, Liu, F, et al. (2017). Blood pressure and heart rate changes during clozapine treatment. Psychiatr Q, 88(3), 545–552.Google Scholar
Novick, D, Haro, JM, Perrin, E, Suarez, D, Texeira, JM (2009). Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol, 19(8), 542–550.Google Scholar
O’Connor, WT, O’Shea, SD (2015). Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments. Pharmacol Ther, 150, 47–80.Google Scholar
Park, YW, Kim, Y, Lee, JH (2012). Antipsychotic-induced sexual dysfunction and its management. World J Mens Health, 30(3), 153–159.Google Scholar
Perdigues, SR, Quecuti, RS, Mane, A, et al. (2016). An observational study of clozapine induced sedation and its pharmacological management. Eur Neuropsychopharmacol, 26(1), 156–161.Google Scholar
Pfuhlmann, B, Hiemke, C, Unterecker, S, et al. (2009). Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol, 29(4), 392–394.Google Scholar
Polcwiartek, C, Nielsen, J (2016). The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. Psychopharmacology, 233(5), 741–750.Google Scholar
Potkin, SG, Basile, VS, Jin, Y, et al. (2003). D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry, 8, 109–113.Google Scholar
Regen, F, Herzog, I, Hahn, E, et al. (2017). Clozapine-induced agranulocytosis: evidence for an immune-mediated mechanism from a patient-specific in-vitro approach. Toxicol Appl Pharmacol, 316, 10–16.Google Scholar
Remington, G, Lee, J, Agid, O, et al. (2016). Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert Opin Drug Saf, 15(9), 1193–1203.Google Scholar
Roberts, CE, Mortenson, LY, Merrill, DB, et al. (2011). Successful rechallenge with clozapine after eosinophilia. Am J Psychiatry, 168(11), 1147–1151.Google Scholar
Rogers, DP, Shramko, JK (2000). Therapeutic options in the treatment of clozapine-induced sialorrhea. Pharmacotherapy, 20(9), 1092–1095.Google Scholar
Ronaldson, KJ, Taylor, AJ, Fitzgerald, PB, et al. (2010). Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry, 71(8), 976–981.CrossRefGoogle ScholarPubMed
Ronaldson, KJ, Fitzgerald, PB, Taylor, AJ, et al. (2012). Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res, 141(2–3), 173–178.Google Scholar
Rostami-Hodjegan, A, Amin, AM, Spencer, EP, et al. (2004). Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol, 24(1), 70–78.Google Scholar
Roth, BL, Driscol, J (2013). PDSP Ki Database. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 10.10.13 from ‘Archived copy’. Archived from the original on 8.11.13. Retrieved 25.11.13.Google Scholar
Samara, MT, Dold, M, Gianatsi, M, et al. (2016). Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry, 73(3), 199–210.Google Scholar
Seeman, P (2014). Clozapine, a fast-off-D2 antipsychotic. ACS Chem Neurosci, 5, 24–29.Google Scholar
Selent, J, Lopez, L, Sanz, F, Pastor, M (2008). Multi-receptor binding profile of clozapine and olanzapine: a structural study based on the new β2 adrenergic receptor template. ChemMedChem, 3, 1194–1198.Google Scholar
Shirazi, A, Stubbs, B, Gomez, L, et al. (2016). Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci, 17(6), 863.CrossRefGoogle ScholarPubMed
Siskind, D, McCartney, L, Goldschlager, R, Kisely, S (2016). Clozapine v. first- and second-generation antipsychotics in treatment refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry, 209(5), 385–392.Google Scholar
Siskind, D, Siskind, V, Kisely, S (2017). Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry, 62(11), 772–777.Google Scholar
Sommer, IE, Begemann, MJ, Temmerman, A, Leucht, S (2012). Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull, 38(5), 1003–1011.Google Scholar
Sommer, IE, van Westrhenen, R, Begemann, MJH, et al. (2014). Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull, 40(1), 181–191.Google Scholar
Stoecker, ZR, George, WT, O’Brien, JB, et al. (2017). Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months. Int Clin Psychopharmacol, 32(3), 155–160.Google Scholar
Suppes, T, Webb, A, Paul, B, et al. (1999). Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry, 156, 1164–1169.CrossRefGoogle Scholar
Suzuki, T, Remington, G, Uchida, H, et al. (2011a). Mangement of schizophrenia in late life with antipsychotic medications. A qualitative review. Drugs Aging, 28(12), 961–980.Google Scholar
Suzuki, T, Uchida, H, Watanabe, K, Kashima, H (2011b). Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol Bull, 44(1), 32–60.Google Scholar
Tanahashi, S, Yamamura, S, Nakagawa, M, Motomura, E, Okada, M (2012). Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol, 165(5), 1543–1555.Google Scholar
Testani, M Jr (1994). Clozapine-induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry, 55(11), 497–498.Google Scholar
Tiihonen, J, Lönnqvist, J, Wahlbeck, K, et al. (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet, 374(9690), 620–627.Google Scholar
Tiihonen, J, Haukka, J, Taylor, M, et al. (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry, 168(6), 603–609.Google Scholar
Tiihonen, J, Mittendorfer-Rutz, E, Majak, M, et al. (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry, 74(7), 686–693.Google Scholar
Veerman, SR, Schulte, PF, Begemann, MJ, de Haan, L (2014). Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Pharmacopsychiatry, 47(7), 231–8.Google Scholar
World Health Organization (WHO) (2017). WHO Model Lists of Essential Medicines, 20th list, 24.1. Geneva: World Health Organization. Available at: www.who.int/medicines/publications/essentialmedicines/en/ (last accessed 9.8.17).Google Scholar
Wu, CS, Wang, SC, Gau, SSF, Tsai, HJ, Cheng, YC (2013). Association of stroke with the receptor-binding profiles of antipsychotics – a case-crossover study. Biol Psychiatry, 73, 414–421.Google Scholar
Wu, CS, Tsai, YT, Tsai, HJ (2015). Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. J Am Heart Assoc, 4(2), e001568.CrossRefGoogle ScholarPubMed
Wu, Y, Blichowski, M, Daskalakis, ZJ, et al. (2011). Evidence that clozapine directly interacts on the GABAB receptor. Neuroreport, 22(13), 637–641.Google Scholar
Xiang, YQ, Zhang, ZJ, Weng, YZ, et al. (2006). Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res, 83(2–3), 201–210.CrossRefGoogle ScholarPubMed
Yang, SY, Liao, YT, Liu, HC, et al. (2013). Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study. J Clin Psychiatry, 74, e79–e86.Google Scholar
Yoshimura, B, Yada, Y, So, R, Takaki, M, Yamada, N (2017). The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res, 250, 65–70.Google Scholar
Yusufi, B, Mukherjee, S, Flanagan, R, et al. (2007). Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int J Psychopharmacol, 22, 238–243.CrossRefGoogle ScholarPubMed
Zheng, W, Xiang, YT, Yang, XH, Xiang, YQ, de Leon, J (2017). Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Clin Psychiatry, 78(5), e498–e505.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×